Amgen (NASDAQ: AMGN) and UCB presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE